Browse All

Current Filters

CLEAR FILTER x

TITLE

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

Author:Giovannoni, Gavin   Airas, Laura   Bove, Riley   Cutter, Gary   Hobart, Jeremy   Kuhle, Jens   Montalban, Xavier   Tur, Carmen   Wolinsky, Jerry   Schneble, Hans-Martin   Baldinotti, Anna   Bonati, Ulrike   Giacobino, Caroline   Wang, Qing   Yang, Ke   Oh, Jiwon   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.001  

Author Institution:Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK and Blizard Institute, Queen Mary University, London, UK, London, United Kingdom  University of Turku, Turku, Finland, Turku, Finland  UCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA, CA  The University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA, Birmingham, AL  Peninsula Medical School, Plymouth University, UK, Plymouth, United Kingdom  MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland, Switzerland  Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Queen Square MS Centre, Department of Neuroinflammation, Institute of Neurology, Faculty of Brain Sciences, University College London (UCL), London, UK/Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (CEMCAT), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, Un  Department of Neurology, University of Texas Health Science Center, Houston, TX, USA, TX  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Switzerland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, ON, Canada  

Humoral Vaccine Responses and One-year Follow-up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analyses of the Prospective, Multicenter, Open-label, Phase IV Studies MINORE and SOPRANINO

Author:Dobson, Ruth   Bove, Riley   Hellwig, Kerstin   Oreja-Guevara, Celia   Derfuss, Tobias J.   Shah, Anna   Graham, Edith L.   McElrath, Thomas F.   Pietrasanta, Carlo   Maillart, Elisabeth   Jacobs, Dina   Kazlauskaite, Agne   Alves, Daniela   Raposo, Catarina   Craveiro, Licinio   Lin, Chien-Ju   Pasquarelli, Noemi   Vukusic, Sandra   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.002  

Author Institution:Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK, London, United Kingdom  Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA, Berkeley, CA  Katholisches Klinikum Bochum, St. Josef Hospital, Universitätsklinikum, Bochum, Germany, Bochum, Germany  Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain, Madrid, Spain  University Hospital Basel, University of Basel, Basel, Switzerland, Basel, Switzerland  Rocky Mountain MS Center, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Multiple Sclerosis and Neuroimmunology, Northwestern University, Chicago, IL, USA, Chicago, IL  Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA  NICU, Department of Woman, Child and Newborn, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, Milan, Italy  Neurology Department, Hôpital de la Pitié Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France, Paris, France  Department of Neurology, Perelman School of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Roche Products Ltd, Welwyn Garden City, UK, Welwyn Garden City, United Kingdom  Service de Neurologie et Sclérose en Plaques, Fondation Eugène Devic EDMUS contre la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Lyon, France, BRON Cedex, France  

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study

Author:Bar-Or, Amit   Oh, Jiwon   Giovannoni, Gavin   Sormani, Maria Pia   Weber, Martin S.   Stoll, Sharon   Nicholas, Jacqueline A.   Büdingen, H.-Christian von   Lopez, Jon   Roberts, Louise   Triyatni, Miriam   Qi, Qi   Ratchford, John N.   Napieralski, Julie   Goodyear, Alexandra   Hauser, Stephen L.   Kappos, Ludwig   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.004  

Author Institution:Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada  Queen Mary University of London, London, UK, London, United Kingdom  University of Genoa, Genoa, Italy, Genoa, Italy  Institute of Neuropathology and Department of Neurology, University Medical Center and Fraunhofer Institute for Translational Medicine and Pharmacology, Göttingen, Germany, Göttingen, Germany  Advocare Stoll Medical Group, Philadelphia, PA, USA, Philadelphia, PA  OhioHealth Multiple Sclerosis Centre, Riverside Methodist Hospital, Columbus, OH, USA, Columbus, OH  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Genentech, Inc., South San Francisco, CA, USA, South San Francisco, CA  University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  University Hospital and University Basel, Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Basel, Switzerland, Basel, Switzerland  

Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Pediatric-onset Relapsing-remitting MS: Results of the Phase III OPERETTA Two Study

Author:Banwell, Brenda   Kotulska, Katarzyna   Rostásy, Kevin   Deiva, Kumaran   Sato, Henry   Filippi, Massimo   Chitnis, Tanuja   Sormani, Maria Pia   Krupp, Lauren   Bar-Or, Amit   Evershed, Joanna   El Azzouzi, Bouchra   Wang, Qing   Lin, Chien-Ju   Hogea, Alexandra   Schneble, Hans-Martin   Manlius, Corinne   Waubant, Emmanuelle   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.005  

Author Institution:Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA, Baltimore, MD  Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Warsaw, Poland, Warsaw, Poland  Pediatric Neurology at Children's Hospital, Datteln, Germany, Datteln, Germany  Department of Pediatrics Neurology, Bicêtre Hospital, Le Kremlin-Bicêtre, France and Paris Sud-Saclay University, Le Kremlin-Bicêtre, France, Le Kremlin-Bicêtre, France  Neurological Institute of Curitiba, Curitiba, PR, Brazil, Curitiba, PR, Brazil  Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit, Neurorehabilitation Unit and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  Department of Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA  DISSAL, University of Genoa, Genoa, Italy, Genoa, Italy  Department of Neurology, NYU Langone Health, New York, NY, USA, New York, NY  Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Roche Products Ltd, Welwyn Garden City, UK, Welwyn Garden City, United Kingdom  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Neurology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  

Week 96 Analysis of the OCARINA II Study Characterizing Subcutaneous Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis

Author:Newsome, Scott D.   Goldstick, Lawrence   Selmaj, Krzysztof   Krzystanek, Ewa   Zecevic, Dusanka   Clinch, Susanne   Giacobino, Caroline   Azmi, Jay   Figueiredo, Catarina   Centonze, Diego   

Session Name:P7: Multiple Sclerosis: Clinical Trials 1  

Topic:Multiple Sclerosis  

Program Number:P7.006  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD, USA, Baltimore, MD  Department of Neurology and Rehabilitation Waddell Center for Multiple Sclerosis, University of Cincinnati, College of Medicine, Cincinnati, OH, USA, Dayton, OH  Centrum Neurologii, Lódz, Poland and Department of Neurology, University of Warmia & Mazury, Olsztyn, Poland, Poland  Department of Neurology, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland, Katowice, Poland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Roche Products Ltd, Welwyn Garden City, UK, United Kingdom  Department of Systems Medicine, Tor Vergata University, Rome, Italy and Unit of Neurology, IRCCS Neuromed, Pozzilli (IS), Italy, Italy